35th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150238493 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES - The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkinson's disease, anemia, cytopenia those among the diagnostic criteria. | 2015-08-27 |
20150238494 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF - The invention provides nutritional supplements, in powder, tablet or capsule dosage forms and aqueous formulations, containing one or more of the purine bioactive compounds described including theacrine and theacrine species. | 2015-08-27 |
20150238495 | Treatment or Prevention of Fungal Infections with PDK1 Inhibitors - Provided are methods of treating or preventing a fungal infection in a subject. The methods comprise identifying a subject with or at risk of developing a fungal infection and administering to the subject a therapeutically effective amount of an inhibitor or a fungal phosphoinositide-dependent kinase 1 (PDK-1) or a homolog thereof. Inhibition of the fungal PDK-1 or homolog thereof results in the treatment or prevention of a fungal infection in the subject. Also provided are compositions comprising an inhibitor of a fungal phosphoinositide-dependent kinase 1 (PDK-1) or a homolog thereof, and a pharmaceutically acceptable carrier. | 2015-08-27 |
20150238496 | ANTIVIRAL THERAPY - The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC | 2015-08-27 |
20150238497 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 2015-08-27 |
20150238498 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS - Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV). | 2015-08-27 |
20150238499 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH - Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed. | 2015-08-27 |
20150238500 | PYRROLE ANTIFUNGAL AGENTS - The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides. | 2015-08-27 |
20150238501 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT - Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections. | 2015-08-27 |
20150238502 | Compositions and Methods for Treating Stroke - Provided herein is a method of treating a subject believed to have suffered a stroke. This method comprises administering to the subject therapeutically effective amount of a composition comprising conivaptan or an active derivative, stereoisomer, pro-drug, or pharmaceutically acceptable salt thereof. | 2015-08-27 |
20150238503 | LOW DOSE NORIBOGAINE FOR TREATING NICOTINE ADDICTION AND PREVENTING RELAPSE OF NICOTINE USE - This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof. | 2015-08-27 |
20150238504 | SALTS AND POLYMORPHS OF 8-FLUORO-2--1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE - The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer. | 2015-08-27 |
20150238505 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine. | 2015-08-27 |
20150238506 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF - The present invention relates to a serotonin 5-HT | 2015-08-27 |
20150238507 | BENZODIAZEPINES FOR TREATING SMALL CELL LUNG CANCER - The present invention relates to the use of a benzodiazepine compound, and its use in the treatment of cancer, particularly small cell lung cancer. | 2015-08-27 |
20150238508 | METHODS FOR MODULATING CORTICOSTERONE LEVELS IN PSYCHOLOGICALLY STRESSED INDIVIDUALS - Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods include administration of 2-fucosyl-lactose to an individual. | 2015-08-27 |
20150238509 | TREATMENT OF SICKLE CELL DISEASE AND INFLAMMATORY CONDITIONS - The invention provides methods and compositions for the treatment of sickle cell disease and other inflammatory conditions. | 2015-08-27 |
20150238510 | STABLE INJECTABLE COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE - The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments. | 2015-08-27 |
20150238511 | SYNERGISTIC ANTIVIRAL COMPOSITIONS COMPRISING A VIRAL ATTACHMENT INHIBITOR, AN INTEGRATION INHIBITOR, AND A PROVIRAL TRANSCRIPTION INHIBITOR, AND THEIR USE - Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use. | 2015-08-27 |
20150238512 | MEDICINAL CARBOHYDRATES FOR TREATMENT OF RESPIRATORY CONDITIONS - A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition. | 2015-08-27 |
20150238513 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA - Disclosed are compositions and methods for inducing therapeutic hypothermia in a subject. | 2015-08-27 |
20150238514 | Protective Supplement Configuration - An orally ingested supplement is provided having a core formed of NADH which is protected from communication with stomach acid once ingested by both an enteric coating on the core and a surrounding secondary layer formed of CoQ10 which acts to increase energy output from the NADH. Other supplements may be included in the secondary layer and a plurality of cores may also be included with each surrounded by a protective secondary layer. | 2015-08-27 |
20150238515 | ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES - The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS. | 2015-08-27 |
20150238516 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS - The disclosure provides methods and compositions for delivering polynucleotides into cells. The disclosure provides transiently protected polynucleotides comprising an anionic charge-neutralizing moiety/group, which may also confer additional functionality. These compounds can enter the cytosol of cells by endocytic or macropinocytic mechanisms. The transient protecting group is bioreversible, i.e., once inside a cell, it is designed to be removed by enzymatic activity or by passive intracellular methods (e.g., changes in pH or reductive environment). | 2015-08-27 |
20150238517 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Treatment of cancer by regional and prolonged release of one or more nucleotide-based agents is provided. | 2015-08-27 |
20150238518 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROPSYCHOLOGICAL DEFICITS - Pharmaceutical compositions and methods for the treatment of neuropsychological impairment in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount, and a micronutrient composition containing acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS stimulant and micronutrient components may be in admixture for convenient daily oral administration of a low dosage CNS stimulant and micronutrients in the range of bout 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cystein, and 25-100 mg alpha-lipoic acid per day. | 2015-08-27 |
20150238519 | THERAPY FOR DRUG RESISTANT CANCER - Disclosed herein are compositions and methods for treating cancer involving the targeting of FGD4. Alternatively, methods and compositions involve the administration of certain miRNA sequences. The administration is effective to reduce the conversion of cancer cells to an aggressive phenotype. | 2015-08-27 |
20150238520 | ALGINATE OLIGOMERS FOR USE IN OVERCOMING MULTIDRUG RESISTANCE IN BACTERIA - The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes. | 2015-08-27 |
20150238521 | NANOPARTICLE COMPOSITIONS OF ANTIBACTERIAL COMPOUNDS AND OTHER USES THEREOF - The present disclosure relates to the development of antibacterial compounds and their nanoparticle compositions. Methods of making the compounds and their nanoparticle compositions, their use as medicament for the treatment of bacterial infection and also for suppressing potentially harmful inflammation are disclosed. | 2015-08-27 |
20150238522 | COMPOSITION FOR TREATMENT, INHIBITION AND ATTENUATION OF VIRUS - The embodiments herein relate to a therapeutically active composition for the treatment, inhibition or attenuation of a virus. The composition comprises an effective amount of a sulfur containing compound along with one or more pharmaceutically acceptable carriers or excipients. The sulfur containing compound impairs a disulfide bond of a plurality of virus. The plurality of virus includes | 2015-08-27 |
20150238523 | Method of Production of the Stable Selenium-Comprising Pharmaceutical Composition with a High Selenium Level - The present disclosure relates to the new method of producing of the stable selenium-comprising pharmaceutical compositions with a high selenium level based on the mixing of nitric acid with therapeutically effective amounts of at least two active ingredients selected from the groups consisting of 2,2-dichlorocarboxylic acids, selenium-containing compound. As a selenium-containing compound the aqueous solution of selenious acid in the amount of no more than 20%, preferably 0.5-10.0%, is used. The group of 2,2-dichlorocarboxylic acids consists 2,2-dichloropropionic acid and their homologes The chemical process is carried out by adding of the concentrated nitric acid in amount of 1.0-5.0% into 2,2-dichlorocarboxylic acid purity of at least 98.5% and completing the redox-interaction under the isothermal conditions at a temperature not higher than 70° C., preferably at 20-30° C., and then an aqueous solution of the selenious acid in an amount of not more than 20.0% (and the other components if it is necessary) is added to form the result pharmaceutical product solution. The product can also contain additional 5-20% of dimethylsulfoxide. The claimed pharmaceutical product is useful for the treating of benign, viral, premalignant, and malignant non-metastasizing skin lesions, of dysplastic lesions of visible mucous coats, fungous and other skin diseases. | 2015-08-27 |
20150238524 | COMPOSITION AND METHOD FOR TREATING MIGRAINES - Disclosed are compositions for treating or preventing migraine headaches and related headaches. | 2015-08-27 |
20150238525 | INJECTABLE STERILE AQUEOUS FORMULATION BASED ON CROSSLINKED HYALURONIC ACID AND ON HYDROXYAPATITE, FOR THERAPEUTIC USE - This invention relates to an absorbable sterile injectable aqueous formulation that is ready to use, used for therapeutic purposes as a cohesive particle-based viscoelastic gel containing i) cross-linked hyaluronic acid, or one of its salts, at a concentration between 1% and 4% (mass/volume), with the cross-linking that is performed making it possible to obtain a gel having a base of cross-linked hyaluronic acid having a so-called cohesive structure, and ii) hydroxyapatite. at a concentration between 10% and 70% (mass/volume), said hydroxyapatite being in the form of particles having an average size less than or equal to 650 μm; with the said sterile injectable aqueous formulation having viscoelastic properties such that Tan δ at a frequency of 1 Hz is less than or equal to 0.60. | 2015-08-27 |
20150238526 | CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated. | 2015-08-27 |
20150238527 | VITAMIN SUPPLEMENT COMPOSITIONS FOR INJECTION - The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss. | 2015-08-27 |
20150238528 | Formulations Involving Solvent/Detergent-Treated Plasma (S/D Plasma) and Uses Thereof - The invention concerns pharmaceutical formulations comprising solvent/detergent (S/D)-treated plasma and a glycosaminoglycan such as hyaluronic acid, and their use for treating diseases, particularly musculoskeletal diseases. | 2015-08-27 |
20150238529 | PLASMA-SUPPLEMENTED FORMULATION - Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof. | 2015-08-27 |
20150238530 | Depletion of cancer stem cells - Compositions and methods are provided for killing of cancer stem cells, and for the transplantation of pluripotent stem cells and differentiated cells derived therefrom. | 2015-08-27 |
20150238531 | URINE STEM CELLS FOR SKELETAL MUSCLE GENERATION AND USES THEREOF - Provided herein are methods of treating a subject in need of treatment for a urological condition including administering urine stem cells to said subject in a treatment effective amount; and, in conjunction therewith, administering growth factors to said subject in an amount effective to promote differentiation of said stem cells into skeletal muscle cells. Compositions useful for the same are also provided. | 2015-08-27 |
20150238532 | METHODS TO ISOLATE HUMAN MESENCHYMAL STEM CELLS - A method of obtaining a population of PDGFRα | 2015-08-27 |
20150238533 | Composition and Method of Treating Eye Discharge - A composition and method of treating eye discharge for an animal is provided. The composition and method includes providing a dehydrated lamb heart and a dehydrated beef heart. The dehydrated lamb heart and the dehydrated beef heart are combined to form a dehydrated lamb and beef heart mixture. Effective amounts of the dehydrated lamb and beef heart mixture are orally administered to an animal. Dehydrated lamb and beef hearts contain essential vitamins and minerals that help treat and prevent eye discharge in animals. | 2015-08-27 |
20150238534 | NOVEL HOLLOW PARTICLES - A hollow particle is provided. The hollow particle of the invention comprises (a) a hollow microparticle, (b) a plural of linking molecules binding the surface of the microparticle, (c) a polypeptide binding the linking molecule, and (d) a target molecule binding the linking molecule. The hollow microparticle of the invention can deliver more cells and provides a higher rate of cell transplantation by the hollow structures, polypeptides and target molecules. The present invention also provides a manufacture of the hollow microparticle and a cell carrier. | 2015-08-27 |
20150238535 | Method and System for Treatment of Cardiovascular Disorders - Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. | 2015-08-27 |
20150238536 | Method and System for Treatment of Cardiovascular Disorders - Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. | 2015-08-27 |
20150238537 | Method and System for Treatment of Cardiovascular Disorders - Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. | 2015-08-27 |
20150238538 | METHOD FOR IN VITRO PROLIFERATION OF CELL POPULATION CONTAINING CELLS SUITABLE FOR TREATMENT OF ISCHEMIC DISEASE - Simplification of a preparation step of a cell population used for the treatment of ischemic diseases, and provision of a cell population that shows more effect by the treatment. | 2015-08-27 |
20150238539 | COMPOSITION FOR BRAIN-NEURON PROTECTION AND BRAIN-DISEASE PREVENTION, ALLEVIATION OR TREATMENT COMPRISING MUSKRAT MUSK - The present invention relates to a composition for the protection of brain nerve cells and the prevention, alleviation and treatment of brain diseases comprising musk from a muskrat as an active ingredient. The above composition has a superior pharmacological effect in improving nerve regeneration, suppressing damage to nerve cell, and preventing and treating Alzheimer's dementia. | 2015-08-27 |
20150238540 | METHODS FOR TREATING CARDIAC CONDITIONS - Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro. | 2015-08-27 |
20150238541 | CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated. | 2015-08-27 |
20150238542 | METHOD FOR ISOLATING FRACTION HAVING ANTI-INFLAMMATORY OR OSTEOARTHRITIS-INHIBITING EFFECTS BY USING OYSTER SHELL CHIPS - The present invention relates to a method for isolating a fraction having anti-inflammatory or osteoarthritis-inhibiting effects by removing impurities and washing oyster shells, which are produced during a process of producing oysters, drying same, forming a powder from the oyster shells, and adding anhydrous citric acid to same for a reaction, obtaining a reaction product, and isolating a supernatant, which is obtained by centrifugally separating the reaction product, by means of ultrafiltration. By adding the anhydrous citric acid to the oyster shell chips for the reaction at a relatively low temperature, the present invention provides superior advantages, such as significantly reducing energy costs and isolating the fraction having the anti-inflammatory or osteoarthritis inhibiting effects through a simple method. | 2015-08-27 |
20150238543 | COMPOSITIONS AND METHOD FOR TREATING NEUTRALIZING MICROORGANISMS - The present disclosure relates to compositions and methods for targeted killing of microorganisms. In particular, the present disclosure relates to the use of | 2015-08-27 |
20150238544 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | 2015-08-27 |
20150238545 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic | 2015-08-27 |
20150238546 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of | 2015-08-27 |
20150238547 | LACTIC ACID BACTERIUM-CONTAINING PREPARATION - The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium | 2015-08-27 |
20150238548 | LACTOBACILLUS STRAIN, COMPOSITION AND USE THEREOF FOR TREATING SYNDROMES AND RELATED COMPLICATIONS OF AUTOIMMUNE DISEASES - The present invention is related to a | 2015-08-27 |
20150238549 | PROBIOTIC DOSAGE UNITS - A dosage unit including a probiotic component, a pH buffering agent, and a tonicity buffering agent. A dosage unit including a probiotic component, a polymeric matrix component, and a tonicity buffering agent, wherein the tonicity buffering agent is present in an amount and configuration suitable to provide a localized isotonic medium upon addition of the dosage unit to 50 mL of 0.1 N HCl (aq). | 2015-08-27 |
20150238550 | AAV Vectors Targeted to Oligodendrocytes - The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes. | 2015-08-27 |
20150238551 | SANDALWOOD OIL AND ITS USES RELATED TO CLOSTRIDIUM INFECTIONS - Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat, prevent or reduce the recurrence of | 2015-08-27 |
20150238552 | Composition for Use as a Medicine or Dietetic Food in the Prevention and/or Treatment of Diabetes and Diabetes Associated Diseases - The present invention relates to a composition a maximum of six, in particular a maximum of five or four different plant extracts for use in the prevention and/or treatment of diabetes type II or type 1. At least one plant extract has antioxidative properties and/or antioxidant enzyme inducing properties; at least one plant extract has anti-inflammatory properties; at least one plant extract has immune modulating properties; and at least one plant extract has neuronal hormone modulating properties. | 2015-08-27 |
20150238553 | TRIPTERYGIUM WILFORDII EXTRACTS TO OVERCOME CHEMOTHERAPY RESISTANCE - The invention provides extracts and compositions derived from | 2015-08-27 |
20150238554 | METHOD OF MAKING LIQUID OLIVE LEAF EXTRACT - A method of making liquid olive leaf extract that includes the mixing ground olive leaf, water, and an acid in a container. Once mixed heating the mixture a predetermined temperature for approximately four hours. Next raising the pH to approximately 4.0 and then adding a predetermined amount of cellulase and invertase to the mixture. Then the mixture is mixed for a predetermined period of time. After mixing, sediment is remove from the mixture and the pH is adjusted to approximately 3.0. The mixture is then reduced to a concentrate. | 2015-08-27 |
20150238555 | CHEWING GUMS - The present invention relates to chewing gum containing a synergic combination of zinc and vegetable extracts containing polyphenols. Said chewing gum is useful in treating the symptoms of halitosis. | 2015-08-27 |
20150238556 | NEURITOGENIC PEPTIDES - The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the invention include peptide sequences that are derived from the sequence of human erythropoietin or proteins that are homologous of human erythropoietin. | 2015-08-27 |
20150238557 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE - A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods. | 2015-08-27 |
20150238558 | IAP ANTAGONISTS - There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 2015-08-27 |
20150238559 | METHODS OF TREATING RHEUMATOID ARTHRITIS - The present invention relates to methods for the treatment of rheumatoid arthritis. In particular, the present invention relates to methods of treating rheumatoid arthritis with GnRH antagonists in patients with high gonadotropin and/or GnRH levels. | 2015-08-27 |
20150238560 | METHODS AND COMPOSITIONS FOR THE DELAYED TREATMENT OF STROKE - The present invention provides, among other things, method of treating stroke including a step of administering an angiotensin (1-7) peptide to a subject suffering from a stroke, approximately 24 hours after the stroke. In some embodiments, treatment begins more than 24 hours after the stroke. In some embodiments, administration of an angiotensin (1-7) peptide results in a reduction in the intensity, severity, duration, and/or frequency of at least one symptom or feature of the one or more complications of stroke. | 2015-08-27 |
20150238561 | Compositions of GnRH related compounds and processes of preparation - The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. | 2015-08-27 |
20150238562 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF - The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions. | 2015-08-27 |
20150238563 | CYCLOSPORINE EMULSION - The present invention relates to cyclosporine emulsions containing: (i) a cyclosporine, (ii) a natural oil (long chain triglyceride), (iii) a phosphatidylcholine, (iv) glycerol, (v) a pharmaceutically tolerable alkali salt of a free fatty acid, (vi) a medium chain triglyceride-oil, (vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment and (viii) water, and to therapeutic methods using them. | 2015-08-27 |
20150238564 | Pharmaceutical Composition Comprising MicroRNA-30B, MicroRNA-133A, or MicroRNA-202-5P Inhibitor for Inhibiting Cancer - Provided is an anticancer composition, and particularly, a pharmaceutical composition for inhibiting cancer, which includes a microRNA-30b, microRNA-133a, or microRNA-202-5p inhibitor as an active ingredient. The pharmaceutical composition may suppress microRNA-30b, microRNA-133a, or microRNA-202-5p, thereby inhibiting proliferation of cancer cells, and eventually, is expected to be useful for cancer treatment. | 2015-08-27 |
20150238565 | Bacteriocin Derived from Lactobacillus rhamnosus - Provided is a bacteriocin that is capable of being easily mass-produced, has high antimicrobial activity even at low concentration, has a wide antimicrobial spectrum, and is less likely to produce resistant microorganisms. The bacteriocin has the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING, or has the same amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING except that one or several amino acids are deleted, substituted, inserted and/or added, wherein the amino acid sequence provides antimicrobial activity and the isoelectric point is not less than 12. | 2015-08-27 |
20150238566 | METHOD OF OBTAINING EFFECTIVE AMOUNTS OF AVIAN FOLLISTATIN - Embodiments of the present invention are generally related to methods of obtaining effective amount of avian follistatin. More specifically, embodiments of the present invention relate to products comprising avian follistatin, and methods of optimizing the same based on avian follistatin concentrations utilized during the manufacturing process. In one embodiment of the present invention, a method of creating a consumable product for treatment of a muscle degenerating disease having avian follistatin comprises selecting an avian egg based upon a desired threshold of avian follistatin concentration therein; extracting material from the avian egg, the material comprising avian follistatin; and processing the material with one or more excipients to yield the consumable product. | 2015-08-27 |
20150238567 | COMPOSITIONS, FORMULATIONS AND METHODS OF TREATING PREECLAMPSIA-TYPE DISORDERS OF PREGNANCY - This invention discloses a method of and composition for treating a PE-type disorder in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a TTR polypeptide in admixture with a pharmaceutically acceptable vehicle. | 2015-08-27 |
20150238568 | EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES - Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide. | 2015-08-27 |
20150238569 | Use of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation - Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described. | 2015-08-27 |
20150238570 | THERAPEUTIC AGENT FOR HYPERTHERMIA - An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient. | 2015-08-27 |
20150238571 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2015-08-27 |
20150238572 | PREPARATION FOR PREVENTING OR TREATING TYPE I DIABETES - The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) α-GalCer. | 2015-08-27 |
20150238573 | NUTRITIONAL FOOD AND FEED, COMPOSITION, PROCESSING AND METHOD OF USE - The present invention relates to means for protecting and incorporating bioactive compounds in food or feed formulations used to enhance the health status and growth performance of human and non-human organisms. | 2015-08-27 |
20150238574 | METHOD FOR TREATING BONE LOSS USING PARATHYROID HORMONE - The present invention relates to method for treating bone loss utilizing full length parathyroid hormone. The method dose not increase the risk of osteosarcoma or bone lesions. | 2015-08-27 |
20150238575 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells. | 2015-08-27 |
20150238576 | TOPICAL THERAPEUTIC COMPOSITIONS CONTAINING BROMELAIN - Compositions containing bromelain are disclosed for use as topical therapeutic agents to restore healthy skin, and for immediate and extended relief from itching and irritation associated with contact dermatitis, insect bites, idiopathic itch, chronic itch, hives, psoriasis, seborrhea, eczema and cracked fingertips, skin abrasions, cuts and minor burns as well as other indications. The compositions include lotions, creams and ointments. | 2015-08-27 |
20150238577 | Chimeric Polypeptides and Their Use in Bacterial Decolonization - The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant | 2015-08-27 |
20150238578 | TREATMENT OF DISEASE USING INTER-ALPHA INHIBITOR PROTEINS - The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP. | 2015-08-27 |
20150238579 | METHODS FOR ASSEMBLING A PRODUCT FOR MODULATING AN IMMUNOMODULATORY RESPONSE IN HUMANS - Embodiments of the invention provide a method for assembling a propyl propane thiosulfonate (PTSO) product for modulating immune function in healthy and sick humans. The method includes selecting a PTSO based compound for incorporation into a PTSO product. The PTSO based compound includes PTSO having a formula R—SOa-S—R, where R represents n-propyl group (—CH | 2015-08-27 |
20150238580 | GLYCOSIDASE REGIMEN FOR TREATMENT OF INFECTIOUS DISEASE - In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and/or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function. | 2015-08-27 |
20150238581 | Novel Histamine Releaser Contained in Human Sweat - Provided arc a sweat allergy antigen, an antibody capable of binding to the antigen specifically, and others, which are produced utilizing a microorganism-originated protein that exists in sweat allergy patient in a dissolved state or a partial peptide of the protein. | 2015-08-27 |
20150238582 | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE DISORDERS, CNS INJURY AND AGE-RELATED DEMENTIA - A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided. | 2015-08-27 |
20150238583 | DNA Vaccines Encoding Heat Shock Proteins - A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease. | 2015-08-27 |
20150238584 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | 2015-08-27 |
20150238585 | ANTI-HER2 VACCINE BASED UPON AAV DERIVED MULTIMERIC STRUCTURES - The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease. | 2015-08-27 |
20150238586 | Rapid Method Production High Purity Cancer Stem Cells and Population of High Purity Cancer Stem Cells - The disclosure provides reagents, including cells, and related methods, useful for administering to subjects with a neoplastic disorder. The reagents and methods encompass cancer stem cells of enhanced purity. Neoplastic disorder encompasses melanoma, ovarian cancer, colorectal cancer, breast cancer, and lung cancer. | 2015-08-27 |
20150238587 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 2015-08-27 |
20150238588 | NOVEL POLYSACCHARIDE AND USES THEREOF - Provided herein is a novel | 2015-08-27 |
20150238589 | Personalized Site-Specific Immunomodulation - The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen. | 2015-08-27 |
20150238590 | USE OF THE SALMONELLA SPP TYPE III SECRETION PROTEINS AS A PROTECTIVE VACCINATION - serotype Typhimurium is a causative agent for gastroenteritis. It is the leading cause of hospitalization and death caused by a food-borne pathogen in the US. As is the case with many gram- negative pathogens, | 2015-08-27 |
20150238591 | Multifunctional Oral Vaccine Based on Chromosome Recombineering - A recombineered | 2015-08-27 |
20150238592 | RECOMBINANT MEASLES VIRUS EXPRESSING CHIKUNGUNYA VIRUS POLYPEPTIDES AND THEIR APPLICATIONS - The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus. | 2015-08-27 |